Abstract
Epidermal growth factor receptor (EGFR) as a transmembrane tyrosine kinase receptor frequently overexpresses in tumors with epithelial origin. The L2 domain from extracellular part of EGFR is involved in ligand binding and the blockage of this domain prevents activation of related signaling pathways. This study was aimed to develop a novel human scFv against EGFR L2 domain as a promising target for cancer therapy. The L2 recombinant protein was purified and used for panning a human scFv phage library (Tomlinson I). In this study, a novel screening strategy was applied to select clones with high binding and enrichment of rare specific phage clones of the L2 protein. After five biopanning rounds several specific clones were isolated which among them one phage clone with high binding was purified for further analysis. The specific interaction of selected clone against target antigen was confirmed by ELISA and western blotting. Immunofluorescence staining showed that purified scFv binds to A431 cells surface, displaying EGFR surface receptor. In the present study, we isolated for the first time a novel human scFv against EGFR L2 domain. This study can be the groundwork for developing more effective diagnostic and therapeutic agents against EGFR overexpressing cancers using this novel human anti-L2 ScFv.
Keywords: Human single chain antibody, cancer, EGFR L2 domain, phage display.
Current Pharmaceutical Design
Title:Development of a Novel Human scFv Against EGFR L2 Domain by Phage Display Technology
Volume: 23 Issue: 13
Author(s): Leila Rahbarnia, Safar Farajnia*, Hossein Babaei, Jafar Majidi, Kamal Veisi, Shiva Ahdi Khosroshahi and Asghar Tanomand
Affiliation:
- Daneshgah Street, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz,Iran
Keywords: Human single chain antibody, cancer, EGFR L2 domain, phage display.
Abstract: Epidermal growth factor receptor (EGFR) as a transmembrane tyrosine kinase receptor frequently overexpresses in tumors with epithelial origin. The L2 domain from extracellular part of EGFR is involved in ligand binding and the blockage of this domain prevents activation of related signaling pathways. This study was aimed to develop a novel human scFv against EGFR L2 domain as a promising target for cancer therapy. The L2 recombinant protein was purified and used for panning a human scFv phage library (Tomlinson I). In this study, a novel screening strategy was applied to select clones with high binding and enrichment of rare specific phage clones of the L2 protein. After five biopanning rounds several specific clones were isolated which among them one phage clone with high binding was purified for further analysis. The specific interaction of selected clone against target antigen was confirmed by ELISA and western blotting. Immunofluorescence staining showed that purified scFv binds to A431 cells surface, displaying EGFR surface receptor. In the present study, we isolated for the first time a novel human scFv against EGFR L2 domain. This study can be the groundwork for developing more effective diagnostic and therapeutic agents against EGFR overexpressing cancers using this novel human anti-L2 ScFv.
Export Options
About this article
Cite this article as:
Rahbarnia Leila, Farajnia Safar*, Babaei Hossein, Majidi Jafar, Veisi Kamal, Khosroshahi Ahdi Shiva and Tanomand Asghar, Development of a Novel Human scFv Against EGFR L2 Domain by Phage Display Technology, Current Pharmaceutical Design 2017; 23 (13) . https://dx.doi.org/10.2174/1381612822666160928112208
DOI https://dx.doi.org/10.2174/1381612822666160928112208 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Inflammation: A Review of Recent Advances in Anti- Inflammatory Strategies
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Targeting of Hypoxia in AQ4N-treated Tumour Xenografts by MALDIIon Mobility Separation-Mass Spectrometry Imaging
Current Analytical Chemistry Aging, Mitochondria and Male Reproductive Function
Current Aging Science Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Phytochemical Screening, Antiproliferative and Antioxidant Properties of Various Extracts from Endemic Origanum acutidens
Combinatorial Chemistry & High Throughput Screening Radiation-Induced Response of Micro RNA Expression in Murine Embryonic Stem Cells
Medicinal Chemistry A Hybrid Brain Tumor Classification and Detection Mechanism Using Knn and Hmm
Current Medical Imaging The Structure and Main Functions of Aminopeptidase N
Current Medicinal Chemistry The Pathophysiology of Oxaliplatin-Induced Neurotoxicity
Current Medicinal Chemistry Topical Melatonin Niosome Gel for the Treatment of 5-FU-Induced Oral Mucositis in Mice
Current Drug Delivery Plant-Derived Biomolecules and Drug Delivery Systems in the Treatment of Liver and Kidney Diseases
Current Pharmaceutical Design A Trojan Horse in Drug Development: Targeting of Thapsigargins Towards Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Economics of Pharmacogenomics: Rethinking Beyond QALYs?
Current Pharmacogenomics and Personalized Medicine Potentials of PKC in Cancer Progression and Anticancer Drug Development
Current Drug Discovery Technologies The Effects of Tamoxifen on Immunity
Current Medicinal Chemistry Development of Computer-AidedCognitive Training Program for Elderly and Its Effectivenessthrougha 6 Months Group Intervention Study
Current Alzheimer Research Subject Index To Volume 9
Current Medicinal Chemistry Prodrugs for Nitroreductase Based Cancer Therapy- 1: Metabolite Profile, Cell Cytotoxicity and Molecular Modeling Interactions of Nitro Benzamides with Ssap-NtrB
Medicinal Chemistry Nutritional Assessment in the Critically Ill Child
Current Pediatric Reviews Inhibition of Procarcinogen Activating Enzyme CYP1A2 Activity and Free Radical Formation by Caffeic Acid and its Amide Analogues
Drug Metabolism Letters